Orthofix Medical Inc. Business Acquisition, Pro Forma Net Income (Loss)
Orthofix Medical Inc. (OFIX) reported Business Acquisition, Pro Forma Net Income (Loss) of -$116.40 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2024-03-05
- Orthofix Medical Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-12-31 was -$19.90M.
- Orthofix Medical Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-09-30 was -$21.20M.
- Orthofix Medical Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-06-30 was -$30.10K.
- Orthofix Medical Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-03-31 was -$45.20M.
- Orthofix Medical Inc. business acquisition, pro forma net income (loss) for fiscal 2023 was -$116.40M.
- Orthofix Medical Inc. business acquisition, pro forma net income (loss) for fiscal 2022 was -$129.20M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$19.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$41.10M derived: sum of 2 quarters · filed 2024-03-05 | -$41.13M derived: sum of 3 quarters · filed 2024-03-05 | -$116.40M 10-K · filed 2024-03-05 |
| 2023-09-30 | -$21.20M 10-Q · filed 2023-11-08 | -$21.23M derived: sum of 2 quarters · filed 2023-11-08 | -$96.50M 10-Q · filed 2023-11-08 | -$93.23M derived: sum of 4 quarters · filed 2024-03-05 |
| 2023-06-30 | -$30.10K 10-Q · filed 2023-08-08 | -$75.30K 10-Q · filed 2023-08-08 | -$72.03M derived: sum of 3 quarters · filed 2024-03-05 | -$104.53M derived: sum of 4 quarters · filed 2024-03-05 |
| 2023-03-31 | -$45.20M 10-Q · filed 2023-05-09 | -$72.00M derived: sum of 2 quarters · filed 2024-03-05 | -$104.50M derived: sum of 3 quarters · filed 2024-03-05 | -$104.53M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-12-31 | -$26.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$59.30M derived: sum of 2 quarters · filed 2024-03-05 | -$59.33M derived: sum of 3 quarters · filed 2024-03-05 | -$129.20M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$32.50M 10-Q · filed 2023-11-08 | -$32.53M derived: sum of 2 quarters · filed 2023-11-08 | -$102.40M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$27.10K 10-Q · filed 2023-08-08 | -$69.90K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$42.60M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |